Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-Guided PD-1 Consolidation in Esophageal Cancer
NCT06498752Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
A Phase 2 trial of PD-1 Monoclonal Antibody in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2024; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06498752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498752.